Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Rectal TOP1288 in Healthy and UC Subjects
NCT02463045Phase 1Completed
- Sponsor
- TopiVert Pharma Limited
- Start
- May 2015
- Primary completion
- Jul 2016
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TOP-1288 in ulcerative colitis (UC) (10 arms), sponsored by TopiVert Pharma Limited. Primary endpoints: Safety as measured by adverse events, Safety as measured by clinical laboratory tests and 2 more. Started May 2015; status: completed.
02
Drugs
TOP-1288
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02463045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02463045.